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Purpose of the study
The association between loss of bone mineral density
(BMD) and PI use is evidenced on several in vitro models
and seems to have different etiology depending on spe-
cific molecule. Although an HAART regimen always con-
tains one or more transcriptase inhibitors, there are no
specific data available regarding specific PI action on
BMD. However, some in vitro experiments showed that
these compounds might induce the differentiation of
osteoclast cells. In order to analyse the specific effect of
each PI on human osteoblast we analysed OPG and
RANKL levels after exposing the cells to each PI.
Methods
We performed two double-blind test and exposed for 24
hours a line of human osteoblast cells to suboptimal,
therapeutic and toxic plasmatic levels of PI: indinavir 1
μg/mL, 5 μg/mL, 25 μg/mL, ritonavir 0.4 μg/mL, 2 μg/mL,
10 μg/mL, μg/mL, fosamprenavir 1.4 μg/mL, 7 μg/mL, 35
μg/mL, tipranavir 1 μg/mL, 5 μg/mL, 25 μg/mL, atazana-
vir 0.6 μg/mL, 3 μg/mL, 15 μg/mL, lopinavir/r 0.8 μg/mL,
4 μg/mL, 20 μg/mL, and darunavir 2 μg/mL, 6 μg/mL, 30
μg/mL, respectively. Tests with nelfinavir and saquinavir
are ongoing. OPG and RANKL were quantified by ELISA
kits purchased from Peprotech and R&D. Statistical analy-
sis was performed using two-tailed Student's test.
Summary of results
We generally noticed in all cases a change in all the values
from baseline, an extremely wide variability in the results
of OPG and RANKL levels, not only between different PIs,
but even between the three pre-determined concentra-
tions for every single PI. Of note, at therapeutic concentra-
tion, FPV (OPG 5.36961 μg/mL, RANKL 0.301362 μg/
mL) and ATV (OPG 5.477401 μg/mL, RANKL 0.464873
μg/mL) showed the best performance.
Conclusion
In a line of human osteoblast cells after exposition to dif-
ferent concentrations of PIs: 1) there is always a variation
of OPG and RANKL levels from baseline; 2) there is an
evident association between PI use and OPG and RANKL
levels; 3) each single PI shows a specific different effect on
OPG and RANKL levels; 4) the concentration of each sin-
gle PI produces a different effect on OPG and RANKL lev-
els; and 5) FPV and ATV shows the best performance. Not
generally the class of PI, but each single PI, and its specific
plasma level, by altering OPG and RANKL levels, may spe-
cifically act on HAART-related loss of BMD, suggesting an
interesting mechanism and role of PI, and accounting for
the different rates of osteoporosis/osteopenia described in
the trials with different PIs.
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